Literature DB >> 31971239

Temporal Gut Microbial Changes Predict Recurrent Clostridiodes Difficile Infection in Patients With and Without Ulcerative Colitis.

Allen A Lee1, Krishna Rao2, Julajak Limsrivilai3, Merritt Gillilland1, Benjamin Malamet4, Emily Briggs1, Vincent B Young2,5, Peter D R Higgins1.   

Abstract

BACKGROUND: Ulcerative colitis (UC) carries an increased risk of primary and recurrent Clostridiodes difficile infection (rCDI), and CDI is associated with UC flares. We hypothesized that specific fecal microbial changes associate with UC flare and rCDI.
METHODS: We conducted a prospective observational cohort study of 57 patients with UC and CDI, CDI only, and UC only. Stool samples were collected at baseline, at the end of antibiotic therapy, and after reconstitution for 16S rRNA sequencing. The primary outcomes were recurrent UC flare and rCDI. Logistic regression and Lasso models were constructed for analysis.
RESULTS: There were 21 (45.7%) patients with rCDI, whereas 11 (34.4%) developed UC flare. Patients with rCDI demonstrated significant interindividual (P = 0.008) and intraindividual differences (P = 0.004) in community structure by Jensen-Shannon distance (JSD) compared with non-rCDI. Two cross-validated Lasso regression models predicted risk of rCDI: a baseline model with female gender, hospitalization for UC in the past year, increased Ruminococcaceae and Verrucomicrobia, and decreased Eubacteriaceae, Enterobacteriaceae, Lachnospiraceae, and Veillonellaceae (AuROC, 0.94); and a model 14 days after completion of antibiotics with female gender, increased Shannon diversity, Ruminococcaceae and Enterobacteriaceae, and decreased community richness and Faecalibacterium (AuROC, 0.9). Adding JSD between baseline and post-treatment samples to the latter model improved fit (AuROC, 0.94). A baseline model including UC hospitalization in the past year and increased Bacteroidetes was associated with increased risk for UC flare (AuROC, 0.88).
CONCLUSION: Fecal microbial features at baseline and after therapy predict rCDI risk in patients with and without UC. These results may help risk stratify patients to guide management.
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Clostridiodes difficile infection; Lasso regression; gut microbiota; predictive modeling; ulcerative colitis

Mesh:

Substances:

Year:  2020        PMID: 31971239      PMCID: PMC7755141          DOI: 10.1093/ibd/izz335

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  33 in total

1.  Genome-based phylogeny and taxonomy of the 'Enterobacteriales': proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov.

Authors:  Mobolaji Adeolu; Seema Alnajar; Sohail Naushad; Radhey S Gupta
Journal:  Int J Syst Evol Microbiol       Date:  2016-09-11       Impact factor: 2.747

2.  Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.

Authors:  Sahil Khanna; Emmanuel Montassier; Bradley Schmidt; Robin Patel; Daniel Knights; Darrell S Pardi; Purna Kashyap
Journal:  Aliment Pharmacol Ther       Date:  2016-08-02       Impact factor: 8.171

3.  Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile.

Authors:  M F De La Cochetière; T Durand; V Lalande; J C Petit; G Potel; L Beaugerie
Journal:  Microb Ecol       Date:  2008-01-22       Impact factor: 4.552

Review 4.  Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Krishna Rao; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

5.  Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study.

Authors:  Roshan Razik; Amir Rumman; Zoya Bahreini; Allison McGeer; Geoffrey C Nguyen
Journal:  Am J Gastroenterol       Date:  2016-05-24       Impact factor: 10.864

6.  Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

Authors:  Derrick W Crook; A Sarah Walker; Yin Kean; Karl Weiss; Oliver A Cornely; Mark A Miller; Roberto Esposito; Thomas J Louie; Nicole E Stoesser; Bernadette C Young; Brian J Angus; Sherwood L Gorbach; Timothy E A Peto
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

7.  Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study.

Authors:  Christian Milani; Andrea Ticinesi; Jacoline Gerritsen; Antonio Nouvenne; Gabriele Andrea Lugli; Leonardo Mancabelli; Francesca Turroni; Sabrina Duranti; Marta Mangifesta; Alice Viappiani; Chiara Ferrario; Marcello Maggio; Fulvio Lauretani; Willem De Vos; Douwe van Sinderen; Tiziana Meschi; Marco Ventura
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

8.  Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic Mice.

Authors:  Hiroko Nagao-Kitamoto; Andrew B Shreiner; Merritt G Gillilland; Sho Kitamoto; Chiharu Ishii; Akiyoshi Hirayama; Peter Kuffa; Mohamad El-Zaatari; Helmut Grasberger; Anna M Seekatz; Peter D R Higgins; Vincent B Young; Shinji Fukuda; John Y Kao; Nobuhiko Kamada
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-03-03

9.  Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.

Authors:  Kelly A Shaw; Madeline Bertha; Tatyana Hofmekler; Pankaj Chopra; Tommi Vatanen; Abhiram Srivatsa; Jarod Prince; Archana Kumar; Cary Sauer; Michael E Zwick; Glen A Satten; Aleksandar D Kostic; Jennifer G Mulle; Ramnik J Xavier; Subra Kugathasan
Journal:  Genome Med       Date:  2016-07-13       Impact factor: 11.117

10.  Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls.

Authors:  Alyxandria M Schubert; Mary A M Rogers; Cathrin Ring; Jill Mogle; Joseph P Petrosino; Vincent B Young; David M Aronoff; Patrick D Schloss
Journal:  MBio       Date:  2014-05-06       Impact factor: 7.867

View more
  4 in total

1.  Assessment of Causal Direction Between Gut Microbiota and Inflammatory Bowel Disease: A Mendelian Randomization Analysis.

Authors:  Zi-Jia Zhang; Hong-Lei Qu; Na Zhao; Jing Wang; Xiu-Yan Wang; Rong Hai; Bin Li
Journal:  Front Genet       Date:  2021-02-18       Impact factor: 4.599

2.  Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition.

Authors:  Yanna Zhao; Jiefeng Huang; Tianyi Li; Shuijuan Zhang; Chengping Wen; Lipei Wang
Journal:  J Cell Mol Med       Date:  2022-01-05       Impact factor: 5.310

3.  The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice.

Authors:  Sarah Tomkovich; Joshua M A Stough; Lucas Bishop; Patrick D Schloss
Journal:  mSphere       Date:  2020-10-21       Impact factor: 4.389

4.  Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration.

Authors:  Ken Blount; Courtney Jones; Dana Walsh; Carlos Gonzalez; William D Shannon
Journal:  Front Microbiol       Date:  2022-01-04       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.